Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection

Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2021-07, Vol.27 (14), p.3809-3811
Hauptverfasser:	Benjamin, Robert S, Minotti, Giorgio
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiotoxicity - etiology Cardiotoxicity - prevention & control Dexrazoxane Doxorubicin - adverse effects Humans Razoxane Sarcoma - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Doxorubicin cardiac toxicity is widely misunderstood, largely preventable, and starts with the first dose. This article reviews the history of doxorubicin cardiac toxicity and strategies for minimizing it. Dexrazoxane cardioprotection can safely be initiated on day 1 without compromising antitumor activity, allowing doxorubicin administration beyond the reported maximum lifetime dose. .
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.CCR-21-1376